Renaissance Technologies LLC increased its position in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 26.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,783,100 shares of the medical research company’s stock after acquiring an additional 378,176 shares during the period. Renaissance Technologies LLC owned about 4.97% of Genomic Health worth $125,209,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of GHDX. Globeflex Capital L P acquired a new stake in Genomic Health in the second quarter valued at approximately $116,000. Sun Life Financial INC acquired a new stake in Genomic Health in the second quarter valued at approximately $122,000. Trexquant Investment LP acquired a new stake in Genomic Health in the third quarter valued at approximately $202,000. SG Americas Securities LLC acquired a new stake in Genomic Health in the second quarter valued at approximately $162,000. Finally, D.A. Davidson & CO. acquired a new stake in Genomic Health in the third quarter valued at approximately $234,000. Institutional investors and hedge funds own 89.21% of the company’s stock.
In related news, insider James J. Vaughn sold 25,000 shares of Genomic Health stock in a transaction on Monday, October 8th. The shares were sold at an average price of $65.34, for a total transaction of $1,633,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Steven Shak sold 5,500 shares of Genomic Health stock in a transaction on Monday, September 10th. The stock was sold at an average price of $63.05, for a total transaction of $346,775.00. The disclosure for this sale can be found here. Insiders have sold 1,635,985 shares of company stock valued at $126,469,701 in the last three months. 45.80% of the stock is owned by insiders.
A number of analysts have weighed in on GHDX shares. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research report on Wednesday, August 29th. BidaskClub lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Raymond James started coverage on shares of Genomic Health in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Finally, Canaccord Genuity reiterated a “buy” rating and set a $82.00 price target (up previously from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $48.33.
Shares of NASDAQ:GHDX opened at $72.90 on Friday. The firm has a market cap of $2.73 billion, a PE ratio of 92.07 and a beta of 0.40. Genomic Health, Inc. has a 52 week low of $26.54 and a 52 week high of $92.18.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The company had revenue of $101.30 million for the quarter, compared to analyst estimates of $94.27 million. During the same quarter in the previous year, the business earned ($0.06) earnings per share. Genomic Health’s revenue was up 23.2% compared to the same quarter last year. Research analysts forecast that Genomic Health, Inc. will post 1.06 EPS for the current year.
WARNING: “Renaissance Technologies LLC Has $125.21 Million Position in Genomic Health, Inc. (GHDX)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/08/renaissance-technologies-llc-has-125-21-million-position-in-genomic-health-inc-ghdx.html.
Genomic Health Profile
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Recommended Story: Systematic Risk and Investors
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.